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tolerance for other systemic therapies (eg, cyclosporin,
methotrexate, psoralen–UV-A) or whose disease failed
to respond to such treatments.
Nail psoriasis is seen in 50% of patients with psoriasis
and in about 80%of patientswith psoriatic arthritis.4 The
managementofnail psoriasis canbevery challenging.The
choice of treatment depends on the clinical presentation
andspecificpatient factors. Systemic treatment is indicated
whennail psoriasis is severe or extensive skin lesions and
psoriatic arthritis coexist orwhen topical treatment fails.
In our patient, ustekinumab proved rapidly effica-
cious in the treatment of nail disease, improving his nail
abnormality-induced psychological stress. Our findings
are in agreement with existing limited data regarding the
effectiveness of ustekinumab in nail psoriasis.5
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Multiple Desmoplastic Melanomas
in Birt-Hogg-Dubé Syndrome and
a Proposed Signaling Link Between
Folliculin, the mTOR Pathway,
and Melanoma Susceptibility
B irt-Hogg-Dube´ syndrome (BHDS) is a rare auto-somal dominant disorder characterized by the de-velopment of cutaneous and systemic tumors.1 The
BHD gene (OMIM 135150) codes for the protein follicu-
lin, which is expressed in multiple tissues including kid-
ney, lung, and skin.1 Folliculin is thought to play a role in
tumor suppression exerting an inhibitory effect on the
growth-promoting mammalian target of rapamycin
(mTOR) pathway.2 Mutations observed within the BHD
gene in BHDS lead to the expression of inactive folliculin,
ultimately resulting in mTOR pathway activation.3 Un-
regulatedmTORactivation promotes cell growth and pro-
liferation, as observed in melanoma pathogenesis.3,4
Report of a Case. A 58-year-old man was seen for mul-
tiple, histologically proven, facial fibrofolliculomas
(Figure 1A and B) raising the possibility of BHDS. He
had a history of spontaneous pneumothoraces in his third
Figure 2. Substantial improvement of psoriasis on the right thumbnail after
the first injection of ustekinumab.
Figure 3. Complete cure of psoriasis on the right thumbnail at week 8,
4 weeks after the second injection of ustekinumab.
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decade of life and a left submandibular salivary oncocy-
toma in 2002.We confirmed BHDS via detection of a pre-
viously reported, heterozygous, truncating, insertional
mutation within the BHD gene (c.1285_1286insC).2 Re-
nal tract ultrasonography and chest, abdomen, and pel-
vis computed tomographic findings were unremarkable.
Twenty-one years earlier, he developed a desmoplas-
tic melanoma on his right cheek (Breslow thickness, 0.5
mm; Clark level, 3) requiring a regional lymphadenec-
tomy for cervical lymph node metastases 3 years later.
In 2006, he developed a lentigomaligna on his right cheek
at the site of his primary desmoplasticmelanoma. In June
2009, he developed a second desmoplastic melanoma
(Breslow thickness, 2.4 mm; Clark level, 4) on his left
shoulder (Figure 1C).
Comment. This patient developed 2 desmoplastic mela-
nomas, which are an uncommon, locally aggressive vari-
ant representing 1% to 3% of melanomas. Melanoma has
been previously reported in 6 patients with BHDS,1,2,5 al-
though none hadmultiple or recurrent lesions. The BHD
gene mutations in 4 of these 6 occurred within a muta-
tional “hot spot” in a highly conserved 700-kb region of
the BHD gene on chromosome 17p11.2.1,2
Though the exact functionof the highly conservedBHD
gene product folliculin remains unknown, experimen-
tal evidence suggests that it has a role in tumor suppres-
sion.2 Figure 2 illustrates the complex series of inter-
actions between folliculin and the growth-promoting
mTORpathway.3 Inactive folliculin, as expressed in BHDS,
being unable to bind to active adenosinemonophosphate–
activated protein kinase (Figure 2), might lead tomTOR
activation and uncontrolled cell growth.1,2
Dysregulation of themTORpathway is associatedwith
theputativepathogenicpathwaysofbenignandmalignant
tumors and, more recently, has been considered as a can-
didate target for melanoma therapy.3,4 The mTOR inhibi-
torrapamycindecreasescellgrowthandproliferationinvitro
and tumor proliferation in vivo.3,4 It has yielded encourag-
ing invitroand invivodatawhenused incombinationwith
other cytotoxic agents to treat metastatic melanoma.6
Establishing incidence vs coincidence for malignant
associations with rare conditions like BHDS is difficult.
While the question ofwhethermutated folliculin in BHDS
predisposes patients to melanoma requires further in-
vestigation, it raises the possibility of the potential use
of mTOR inhibitors in BHDS as a treatment option for
the range of associated malignant neoplasms.3,6
A B C
Figure 1. Clinical and histopathologic images. A, Multiple small skin-colored papules on the nose and cheek. Note site of prior melanoma excision and grafting on
right cheek. B, Photomicrograph of fibrofolliculoma exhibiting an expanded follicular structure with internal strands of epithelium surrounded by loose connective
tissue with an increase in fibroblasts (hematoxylin-eosin, original magnification 4). C, Featureless nodule on left shoulder; histologic analysis showed a
desmoplastic melanoma with a Breslow thickness of 2.4 mm.
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Figure 2. The putative interaction of the folliculin/FNIP1/FNIP2/AMPK complex
with the mammalian target of rapamycin (mTOR) pathway in melanoma. The
BHDmutation in Birt-Hogg-Dube´ syndrome leads to folliculin inactivation and
thus to mTOR activation and may therefore play an additional role in tumor
promotion. Rapamycin and its analogs inhibit mTOR and may compensate for
the inactive folliculin/FNIP1/FNIP2/AMPK complex. AKT indicates
proto-oncogene serine-threonine protein kinase; AMPK, adenosine
monophosphate–activated protein kinase; FNIP, folliculin interacting protein;
MAPK, mitogen-activated protein kinase; mTORC1, mTOR/raptor complex;
mTORC2, mTOR/rictor complex; PI3K, phosphatidylinositol 3-kinase;
Rheb, GTP-binding protein Ras homolog enriched in brain; TSC1/2, tuberous
sclerosis complex 1/2.
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Localized Porokeratosis Secondary
to Ionizing Radiotherapy
for Prostate Carcinoma
S egmental porokeratosis developing after elec-tron beam radiotherapy for follicular lymphomahas been reported once, to our knowledge, in the
literature.1 However, the patient in that case could not
recall which areas of skin were irradiated, so the asso-
ciation was open to question. We report a second case,
which we think demonstrates the association evenmore
convincingly.
Report of a Case. Our patient was diagnosed as having
prostate adenocarcinoma and treated with bicalu-
tamide, leuprorelin, and radiotherapy (total radiation
dose, 64 Gy in 32 fractions over 6 weeks) administered
as 1 anterior and 2 lateral fields. (To convert Grays to
rads, multiply by 100.) The anterior field size was
9.08.6 cm. Treatment was completed 7 months after
diagnosis.
He was seen by us 6 years later, at age 76 years, and
had multiple erythematous lesions with raised scaly
margins localized to the natal cleft and medial aspects
of both buttocks (Figure 1). Skin biopsy specimens
(Figure 2) showed several angulated columns of para-
keratin with underlying hypogranulosis and dyskerato-
sis (cornoid lamellae), consistent with a diagnosis of
porokeratosis. Liquid nitrogen cryotherapy successfully
cleared the lesions.
Radiotherapy mapping images confirmed that the
area of porokeratosis coincided exactly with the exit
dose of the anterior radiation field (Figure 3). The
dose received by the skin over the natal cleft was cal-
culated at 28% of the applied dose, ie, 18 Gy, delivered
in 32 fractions of 0.56 Gy.
Figure 1. Multiple erythematous scaly lesions, located in a segmental
distribution in the natal cleft.
Figure 2. Skin biopsy specimen showing hyperkeratosis and parakeratosis
without generalized dysplasia. The angulated column of parakeratin is
associated with underlying hypogranulosis and dyskeratosis (cornoid lamella).
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